**Table S1. Classification and statistics of initial and current treatment regimens for all study participants**.

|  |  |  |
| --- | --- | --- |
|  | **Initial antiretroviral regimen** | **Currrent antiretroviral regimen** |
|  | Total | Younger | Middle-aged | Older | Total | Younger | Middle-aged | Older |
| **NRTIs+NNRTIs** | 1529 (94.27) | 409 (93.17) | 594 (95.65) | 526 (93.59) | 1110 (68.43) | 305 (69.48) | 421 (67.79) | 384 (68.33) |
| EFV+3TC+TDF | 617 (38.04) | 168 (38.27) | 234 (37.68) | 215 (38.26) | 561 (34.59) | 173 (39.41) | 222 (35.75) | 166 (29.54) |
| EFV+3TC+AZT | 515 (31.75) | 153 (34.85) | 192 (30.92) | 170 (30.25) | 297 (18.31) | 85 (19.36) | 107 (17.23) | 105 (18.68) |
| NVP+3TC+AZT | 336 (20.72) | 85 (19.36) | 130 (20.93) | 121 (21.53) | 158 (9.74) | 40 (9.11) | 55 (8.86) | 63 (11.21) |
| NVP+3TC+TDF | 7 (0.43) | 1 (0.23) | 3 (0.48) | 3 (0.53) | 31 (1.91) | 7 (1.59) | 8 (1.29) | 16 (2.85) |
| Other | 54 (3.33) | 2 (0.46) | 35 (5.64) | 17 (3.02) | 63 (3.88) | 0 (0.00) | 29 (4.67) | 34 (6.05) |
| **INSTIs** | 20 (1.23) | 4 (0.91) | 3 (0.48) | 13 (2.31) | 206 (12.70) | 56 (12.76) | 80 (12.88) | 70 (12.46) |
| **PIs** | 73 (4.50) | 26 (5.92) | 24 (3.86) | 23 (4.09) | 306 (18.87) | 78 (17.77) | 120 (19.32) | 108 (19.22) |

Categorical data are presented as n (%). NRTIs: nucleoside reverse transcriptase inhibitors, NNRTI: non-nucleoside reverse transcriptase inhibitor, PI: protease inhibitor, INSTI: integrase strand transfer inhibitor, EFV: Efavirenz, 3TC: Lamivudine, AZT: Zidovudine, TDF: Tenofovir, NVP: Nevirapine.